Skip to main content
Erschienen in: Hereditary Cancer in Clinical Practice 1/2004

Open Access 01.02.2004 | Review

A Counselling Model for BRCA1/2 Genetic Susceptibility Testing

verfasst von: Iris van Oostrom, Aad Tibben

Erschienen in: Hereditary Cancer in Clinical Practice | Ausgabe 1/2004

Abstract

When BRCA1/2 genetic susceptibility testing was introduced in the clinic in the mid-nineties, the "Huntington protocol" was used in the counselling of individuals applying for genetic testing. This protocol includes at least three sessions with a certain reflection period before blood sampling. Evidence on the psychological impact of BRCA1/2 genetic susceptibility testing has been accumulating in the last years. We will give a short overview of these psychological studies in order to reflect the need of using the extensive Huntington protocol in the counselling of individuals applying for BRCA1/2 genetic susceptibility testing. A shortened and more flexible BRCA1/2 counselling protocol is delineated, in which the attention is focused on the needs and strengths of the individual.

Introduction

When genetic susceptibility testing for hereditary breast and/or ovarian cancer was introduced in the nineties, professionals were concerned about the psychological consequences of learning one's genetic status. Women carrying a BRCA1/2 mutation have to deal with considerable health risks [13] and are confronted with difficult choices concerning risk management. Mutation carriers can opt for regular surveillance, for prophylactic mastectomy and/or prophylactic bilateral salpingo oophorectomy, and/or for chemoprevention trials. Besides important health risks and the far-reaching impact of risk management options, these women may be psychologically vulnerable due to unresolved loss experiences [4, 5]. Many have witnessed the disease in relatives and have lost a mother or sister, possibly leaving young children behind. Furthermore mutation carriers risk to pass or to have passed the mutation onto their children with all the above-mentioned consequences for them.

The Huntington protocol

Because of the potentially far-reaching implications of BRCA1/2 susceptibility testing, the "Huntington protocol" was adopted for the counselling of unaffected individuals who wanted to know whether they had inherited a familial BRCA1/2 mutation. This "Huntington protocol" has a long history. As the availability of DNA analysis for the HD gene was set to become a reality, the Committee of International Huntington Association and the Working Group on Huntington's disease of the World Federation of Neurology gave consideration to the manner in which these tests should be carried out (IHA/WFN 1994). In general, the guidelines recommend that individuals at risk who participate in predictive testing programmes are seen for two to four counseling sessions, spread over a 3-month period, before disclosure of the test results. Predictive testing requires informed consent by the individual at risk, and the provision of psychological support. If the test is abnormal, counselling must be available for the family and others involved. The starting point is that predictive tests should be offered only to individuals at risk who have had the appropriate counselling, are fully informed, and wish to proceed. Genetic centres providing the predictive test have been committed to the use of the international guidelines. Admittedly, after 15 years, testing centres have developed their own local protocols and guidelines, based on experience and local or national rules, but what they have in common is the requirement for multiple interviews before a test result is disclosed. The number and complexity varies, partly due to the number of associated psychological and other evaluations, but the basic structure involves at least the series shown in Table 1.
Table 1
Predictive testing for Huntington's disease
Session one
   - Sociodemographic details
   - Confirmation of family and clinical data
   - Assessment of impact of HD and test results
   - Assessment of knowledge of HD and presymptomatic testing
   - Reasons for requesting prediction
   - Neurological examination*
Session two
   - Assessment of psychological, personality and social resources (using standardized instruments*)
   - Further counselling and discussion on disclosure session
   - Nomination of professional support
   - Signing of consent form
   - Final blood sample
Session three
   - Disclosure of test results
Formal follow-up
   - 2 days-1 week (telephone)
   - 3 months
   - 12 months
* Genetic centres differ in the application of neurological examination and psychological assessment
The expectation of an increase of test requests for a great variety of hereditary disorders in the near future leads us to reconsider the need for such an extensive, time-consuming protocol in the counselling of individuals at risk, including those who may carry a familial BRCA1/2 mutation. What have the lessons of clinical experience and research provided so far?

The psychological impact of genetic testing

Several psychological studies have now been conducted to determine the psychological impact of genetic susceptibility testing for BRCA1/2. In most studies groups of tested individuals were followed prospectively. Generally, the assessment took place before result disclosure and several weeks or months after result disclosure. Results from these studies suggest that participants generally cope well with genetic susceptibility testing. Non-mutation carriers reported a decline in psychological distress several weeks and months after result disclosure. Mutation carriers showed a stable or decreasing level of distress shortly after result disclosure [68] and up to 12 months after result disclosure [911]. Five years after result disclosure the level of distress increased again in both mutation carriers and non-mutation carriers [12]. On the whole the mean level of psychological distress remained underneath the clinical threshold, indicating little need for intervention [612]. In women affected by cancer also no adverse psychological reactions have been observed following genetic testing. They reported a decrease in anxiety and no change in depression rates one month after result disclosure [13]. Remarkably, the prospect of undergoing genetic testing was rated as less distressing than the high risk status or the diagnosis of cancer by women at risk and women with a personal and familial history of breast and/or ovarian cancer [14].
The occurrence of mental health problems was low. No unusually high levels of psychiatric disorder were detected in a group of 315 unaffected individuals from families with a known mutation of BRCA1/2 [15]. In another study [16] it was concluded that of 211 women with a previous history of breast and/or ovarian cancer and 253 unaffected women at risk remarkably few women reported psychological distress and met criteria for psychiatric disorder like depression, anxiety disorder, or alcohol abuse. Compared to women from primary care and community settings, they had lower rates of psychiatric disorder.
In summary, no elevated distress levels and a low prevalence of mental health problems have been observed both before and after BRCA1/2 genetic susceptibility testing. The participants of the studies described here wanted to know their genetic risk status and may therefore consist of a self-selected and psychologically stable subgroup of at risk individuals. Despite the psychological stability of the majority of the group, we emphasise that a subset of women undergoing genetic susceptibility testing for BRCA1/2 reports a level of distress that warrants clinical attention.

Need for help?

The request for psychological support proved to be rare in the short term [8]. Counselees who were referred for psychosocial help generally had more problems with issues like loss and family or partner relationships than with the concern of developing breast cancer [17]. In the five years following testing about half of the mutation carriers and a third of the non-carriers were found to have asked for professional support for psychological problems [12].
Several efforts have been made to identify counselees who risk suffering from psychological adverse reactions. An important precursor is pre-test psychological distress. Women reporting more psychological distress at the time of blood sampling generally continue to report higher distress levels after receiving the result [7, 8]. In the main these women are younger [5, 15, 18] and interested in prophylactic surgery [5].
Another factor was having an intimate relationship. Unmarried women seeking genetic counselling for a family history of breast/ovarian cancer reported more distress than married women in one study [18]. However another study [19] found equal levels of distress in married and unmarried women, but more distress in women with unhappy marriages. A study by Wylie et al [20] evaluated the effects of the support and distress of spouses on BRCA1/2 mutation carriers. Carriers who perceived their spouse to be anxious and non-supportive had higher distress levels one week after result disclosure than carriers who perceived their spouse to be supportive and anxious or low anxious and non-supportive. Carriers who perceived their spouse to be both supportive and low anxious had the lowest distress levels. In carriers with a non-supportive, anxious spouse at the time of testing, distress remained elevated up to two years after testing. The familial context may also be of importance. BRCA1/2 mutation carriers who were the first to be tested experienced more distress [21]. Non-carrier men reported more distress when they had carrier siblings and carrier women reported more distress when tested siblings had mixed results.
Several other studies have concentrated on coping, like the anticipation of the feelings following a positive result. Women who underestimated their feelings of distress following a positive test result, reported more psychological distress six months after having received the result [22]. A monitoring coping style, i.e. being very vigilant to threatening information, resulted in more psychological distress while waiting for the genetic test result [23], but not after receiving results [11, 23].
Decliners of genetic testing may also be more vulnerable to psychological distress. Women with high levels of baseline distress who declined genetic testing reported an important increase in depression rates [24]. Another study however did not find any psychological vulnerability in a (small) clinical sample of women at risk who did not opt for genetic testing [25].

A BRCA1/2 counselling protocol

Genetic counselling should be tailored to the needs and capacities of its target group. If the target group generally has enough psychological resources to cope with genetic testing, our energy should be directed to the individuals who risk being unable to cope with it. Therefore we suggest adapting the Huntington protocol to the needs and strengths of our BRCA1/2 counselees. The shortened BRCA1/2 protocol we propose is depicted in Table 2. It comprises at least two sessions with a genetic counsellor and additional counselling suited to the needs of the counselee. This BRCA1/2 protocol could serve as a model for genetic susceptibility testing of other hereditary cancers such as HNPCC.
Table 2
Genetic susceptibility testing for BRCA1/2
First counselling session with a genetic counsellor
   - Assessment of a priori knowledge concerning BRCA1/2 mutations and genetic testing and provision of risk Information
   - Assessment of impact of the test result
   - Assessment of need to refer to a psychosocial worker
   - Decision counseling
   - Blood sampling
No blood sampling but a second counselling session with a genetic counsellor or psychosocial worker if:
   - counselee experiences provided information as very unfamiliar or shocking or decision making was not thorough
   - other 'unfinished business' comes up such as relational conflicts, communication problems with relatives, worries about (future) children
   - anticipation of inadequate coping with the test result
   - the counselee is younger than 25
Disclosure session
   - Disclosure of the test result by the genetic counsellor
   - Assessment of need to refer to a psychosocial worker
   - Referral to a specialist (for carriers)
Formal follow-up for mutation carriers:
   - Follow-up interview by phone after 2-3 weeks
   - Optional information seminar with experts (geneticist, oncologist, surgeon, gynaecologist) once a year
   - Optional mutation carrier support group
In the first session, careful exploration of the possible impact of testing upon the individual at risk and others involved enables the counselees and their partners to recognise the potential risk factors for inadequate coping. If there are any such factors, additional professional attention from a psychologist or social worker may be of help to anticipate untoward experiences after disclosure of test results. A second session with the counsellor can be offered when unanticipated information or facts emerge in the first session. This enables the counselee to reflect somewhat longer upon the possible consequences and to be more certain to make a thorough decision. Also after the session in which the test result is disclosed, follow-up support by a psychologist or social worker can be offered if needed. Otherwise a follow-up interview by phone and mentioning the possibilities of additional counselling may be sufficient. It is mandatory for the genetic counsellor to master specific communication skills and knowledge about the psychological risk factors, which enables him to identify those individuals who need additional support.

Current practice and future research

Several centres have already adopted a shortened protocol for counselees who apply for BRCA1/2 genetic susceptibility testing and in the United Kingdom certain centres have shortened the protocol for HNPCC pre-test counselling [26]. Aktan-Collan et al [27] evaluated a shortened protocol for predictive testing for HNPCC, that consisted of two sessions and no provision of additional psychological support. The majority (88%) of counselees were satisfied with the procedure and suggested no changes. The counselees who suggested changes generally asked for more written material, not for more counselling sessions. However half of the counselees indicated that they might have used psychological support if it had been offered to them.
Given these results, we think it is unlikely that the proposed counselling protocol for BRCA1/2 genetic susceptibility testing results in an increase in adverse psychological reactions, but more research is necessary to evaluate which aspects of genetic counselling contribute to thorough decision making [28] and to the emotional well-being of counselees and their partners. Future research should also aim at determining the characteristics of individuals who might benefit from additional psychological support and at disentangling the psychological processes resulting in ineffective coping. This knowledge will enable us to identify these individuals as precisely as possible and to adjust our counselling further to the individual needs of the counselees.

Acknowledgements

The authors would like to thank Hanne Meijers-Heijboer for her valuable feedback on the manuscript.
Literatur
1.
Zurück zum Zitat Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995,56(1):265–271.PubMedCentralPubMed Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995,56(1):265–271.PubMedCentralPubMed
2.
Zurück zum Zitat Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Birch JM, Lindblom A, Stoppa-Lyonnet D, Bignon Y, Borg A, Hamann U, Haites N, Scott RJ, Maugard CM, Vasen H, Seitz S, Cannon-Albright LA, Schofield A, Zelada-Hedman M: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998,62(3):676–689. 10.1086/301749PubMedCentralCrossRefPubMed Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Birch JM, Lindblom A, Stoppa-Lyonnet D, Bignon Y, Borg A, Hamann U, Haites N, Scott RJ, Maugard CM, Vasen H, Seitz S, Cannon-Albright LA, Schofield A, Zelada-Hedman M: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998,62(3):676–689. 10.1086/301749PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF: Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. Am J Hum Genet 2003,72(5):1117–1130. 10.1086/375033PubMedCentralCrossRefPubMed Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF: Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. Am J Hum Genet 2003,72(5):1117–1130. 10.1086/375033PubMedCentralCrossRefPubMed
4.
Zurück zum Zitat Horowitz M, Sundin E, Zanko A, Lauer R: Coping with grim news from genetic tests. Psychosomatics 2001,42(2):100–105. 10.1176/appi.psy.42.2.100CrossRefPubMed Horowitz M, Sundin E, Zanko A, Lauer R: Coping with grim news from genetic tests. Psychosomatics 2001,42(2):100–105. 10.1176/appi.psy.42.2.100CrossRefPubMed
5.
Zurück zum Zitat Lodder LN, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Duivenvoorden HJ, Tibben A, Wagner A, Meer CA, Devilee P, Cornelisse CJ, Niermeijer MF: Presymptomatic testing for BRCA1 and BRCA2: how distressing are the pre-test weeks? J Med Genet 1999,36(12):906–913.PubMedCentralPubMed Lodder LN, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Duivenvoorden HJ, Tibben A, Wagner A, Meer CA, Devilee P, Cornelisse CJ, Niermeijer MF: Presymptomatic testing for BRCA1 and BRCA2: how distressing are the pre-test weeks? J Med Genet 1999,36(12):906–913.PubMedCentralPubMed
6.
Zurück zum Zitat Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, Gold K, Trock B, Main D, Lynch J, Fulmore C, Snyder C, Lemon SJ, Conway T, Tonin P, Lenoir G, Lynch H: RCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 1996, 275: 1885–1892. 10.1001/jama.275.24.1885CrossRefPubMed Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, Gold K, Trock B, Main D, Lynch J, Fulmore C, Snyder C, Lemon SJ, Conway T, Tonin P, Lenoir G, Lynch H: RCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 1996, 275: 1885–1892. 10.1001/jama.275.24.1885CrossRefPubMed
7.
Zurück zum Zitat Croyle RT, Smith KR, Botkin JR, Baty B, Nash J: Psychological response to BRCA1 mutation testing: preliminary findings. Health Psychol 1997, 16: 63–72. 10.1037/0278-6133.16.1.63CrossRefPubMed Croyle RT, Smith KR, Botkin JR, Baty B, Nash J: Psychological response to BRCA1 mutation testing: preliminary findings. Health Psychol 1997, 16: 63–72. 10.1037/0278-6133.16.1.63CrossRefPubMed
8.
Zurück zum Zitat Lodder L, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Duivenvoorden HJ, Tibben A, Wagner A, Meer CA, Ouweland AM, Niermeijer MF: Psychological impact of receiving a BRCA1/BRCA2 test result. Am J Med Genet 2001, 98: 15–24. 10.1002/1096-8628(20010101)98:1<15::AID-AJMG1014>3.0.CO;2-0CrossRefPubMed Lodder L, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Duivenvoorden HJ, Tibben A, Wagner A, Meer CA, Ouweland AM, Niermeijer MF: Psychological impact of receiving a BRCA1/BRCA2 test result. Am J Med Genet 2001, 98: 15–24. 10.1002/1096-8628(20010101)98:1<15::AID-AJMG1014>3.0.CO;2-0CrossRefPubMed
9.
Zurück zum Zitat Schwartz MD, Peshkin BN, Hughes C, Main D, Isaacs C, Lerman C: Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol 2002,20(2):514–520. 10.1200/JCO.20.2.514CrossRefPubMed Schwartz MD, Peshkin BN, Hughes C, Main D, Isaacs C, Lerman C: Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol 2002,20(2):514–520. 10.1200/JCO.20.2.514CrossRefPubMed
10.
Zurück zum Zitat Lodder LN, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Seynaeve C, van Geel AN, Tilanus MM, Bartels CC, Verhoog LC, Brekelmans CT, Burger CW, Niermeijer MF: One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat 2002,73(2):97–112. 10.1023/A:1015269620265CrossRefPubMed Lodder LN, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Seynaeve C, van Geel AN, Tilanus MM, Bartels CC, Verhoog LC, Brekelmans CT, Burger CW, Niermeijer MF: One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat 2002,73(2):97–112. 10.1023/A:1015269620265CrossRefPubMed
11.
Zurück zum Zitat Meiser B, Butow P, Friedlander M, Barratt A, Schnieden V, Watson M, Brown J, Tucker K: Psychological impact of genetic testing in women from high-risk breast cancer families. Eur J Cancer 2002,38(15):2025–2031.CrossRefPubMed Meiser B, Butow P, Friedlander M, Barratt A, Schnieden V, Watson M, Brown J, Tucker K: Psychological impact of genetic testing in women from high-risk breast cancer families. Eur J Cancer 2002,38(15):2025–2031.CrossRefPubMed
12.
Zurück zum Zitat Van Oostrom I, Meijers-Heijboer H, Lodder LN, Duivenvoorden HJ, van Gool AR, Seynaeve C, Meer CA, Klijn JG, van Geel BN, Burger CW, Wladimiroff JW, Tibben A: Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol 2003,21(20):3867–3874. 10.1200/JCO.2003.10.100CrossRefPubMed Van Oostrom I, Meijers-Heijboer H, Lodder LN, Duivenvoorden HJ, van Gool AR, Seynaeve C, Meer CA, Klijn JG, van Geel BN, Burger CW, Wladimiroff JW, Tibben A: Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol 2003,21(20):3867–3874. 10.1200/JCO.2003.10.100CrossRefPubMed
13.
Zurück zum Zitat Wood ME, Mullineaux L, Rahm AK, Fairclough D, Wenzel L: Impact of BRCA1 testing on women with cancer: a pilot study. Genet Test 2000,4(3):265–272. 10.1089/10906570050501489CrossRefPubMed Wood ME, Mullineaux L, Rahm AK, Fairclough D, Wenzel L: Impact of BRCA1 testing on women with cancer: a pilot study. Genet Test 2000,4(3):265–272. 10.1089/10906570050501489CrossRefPubMed
14.
Zurück zum Zitat Coyne JC, Kruus L, Racioppo M, Calzone KA, Armstrong K: What do ratings of cancer-specific distress mean among women at high risk of breast and ovarian cancer? Am J Med Genet 2003,116(3):222–228. 10.1002/ajmg.a.10844CrossRef Coyne JC, Kruus L, Racioppo M, Calzone KA, Armstrong K: What do ratings of cancer-specific distress mean among women at high risk of breast and ovarian cancer? Am J Med Genet 2003,116(3):222–228. 10.1002/ajmg.a.10844CrossRef
15.
Zurück zum Zitat Foster C, Evans DG, Eeles R, Eccles D, Ashley S, Brooks L, Davidson R, Mackay J, Morrison PJ, Watson M: Predictive testing for BRCA1/2: attributes, risk perception and management in a multi-centre clinical cohort. Br J Cancer 2002,86(8):1209–1216. 10.1038/sj.bjc.6600253PubMedCentralCrossRefPubMed Foster C, Evans DG, Eeles R, Eccles D, Ashley S, Brooks L, Davidson R, Mackay J, Morrison PJ, Watson M: Predictive testing for BRCA1/2: attributes, risk perception and management in a multi-centre clinical cohort. Br J Cancer 2002,86(8):1209–1216. 10.1038/sj.bjc.6600253PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Coyne JC, Benazon NR, Gaba CG, Calzone K, Weber BL: Distress and psychiatric morbidity among women from high-risk breast and ovarian cancer families. J Consult Clin Psychol 2000, 68: 864–874. 10.1037/0022-006X.68.5.864CrossRefPubMed Coyne JC, Benazon NR, Gaba CG, Calzone K, Weber BL: Distress and psychiatric morbidity among women from high-risk breast and ovarian cancer families. J Consult Clin Psychol 2000, 68: 864–874. 10.1037/0022-006X.68.5.864CrossRefPubMed
17.
Zurück zum Zitat Hopwood P, Keeling F, Long A, Pool C, Evans G, Howell A: Psychological support needs for women at high genetic risk of breast cancer: some preliminary indicators. Psychooncology 1998,7(5):402–412. 10.1002/(SICI)1099-1611(1998090)7:5<402::AID-PON317>3.3.CO;2-OCrossRefPubMed Hopwood P, Keeling F, Long A, Pool C, Evans G, Howell A: Psychological support needs for women at high genetic risk of breast cancer: some preliminary indicators. Psychooncology 1998,7(5):402–412. 10.1002/(SICI)1099-1611(1998090)7:5<402::AID-PON317>3.3.CO;2-OCrossRefPubMed
18.
Zurück zum Zitat Audrain J, Schwartz MD, Lerman C, Hughes C, Peshkin BN, Biesecker B: Psychological distress in women seeking genetic counselling for breast-ovarian cancer risk: the contributions of personality and appraisal. Ann Behav Med 1997,19(4):370–377. 10.1007/BF02895156CrossRefPubMed Audrain J, Schwartz MD, Lerman C, Hughes C, Peshkin BN, Biesecker B: Psychological distress in women seeking genetic counselling for breast-ovarian cancer risk: the contributions of personality and appraisal. Ann Behav Med 1997,19(4):370–377. 10.1007/BF02895156CrossRefPubMed
19.
Zurück zum Zitat Coyne JC, Anderson KK: Marital status, marital satisfaction, and support processes among women at high risk for breast cancer. J Fam Psychol 1999, 13: 629–641. 10.1037/0893-3200.13.4.629CrossRef Coyne JC, Anderson KK: Marital status, marital satisfaction, and support processes among women at high risk for breast cancer. J Fam Psychol 1999, 13: 629–641. 10.1037/0893-3200.13.4.629CrossRef
20.
Zurück zum Zitat Wylie JE, Smith KR, Botkin JR: Effects of spouses on distress experienced by BRCA1 mutation carriers over time. Am J Med Genet 2003,119C(1):35–44. 10.1002/ajmg.c.10002CrossRefPubMed Wylie JE, Smith KR, Botkin JR: Effects of spouses on distress experienced by BRCA1 mutation carriers over time. Am J Med Genet 2003,119C(1):35–44. 10.1002/ajmg.c.10002CrossRefPubMed
21.
Zurück zum Zitat Smith KR, West JA, Croyle RT, Botkin JR: Familial context of genetic testing for cancer susceptibility: moderating effect of siblings' test results on psychological distress one to two weeks after BRCA1 mutation testing. Cancer Epidemiol Biomarkers Prev 1999, 8: 385–392.PubMed Smith KR, West JA, Croyle RT, Botkin JR: Familial context of genetic testing for cancer susceptibility: moderating effect of siblings' test results on psychological distress one to two weeks after BRCA1 mutation testing. Cancer Epidemiol Biomarkers Prev 1999, 8: 385–392.PubMed
22.
Zurück zum Zitat Dorval M, Patenaude AF, Schneider KA, Kieffer SA, DiGianni L, Kalkbrenner KJ, Bromberg JI, Basili LA, Calzone K, Stopfer J, Weber BL, Garber JE: Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: findings from p53 and BRCA1 testing programs. J Clin Oncol 2000, 18: 2135–2142.PubMed Dorval M, Patenaude AF, Schneider KA, Kieffer SA, DiGianni L, Kalkbrenner KJ, Bromberg JI, Basili LA, Calzone K, Stopfer J, Weber BL, Garber JE: Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: findings from p53 and BRCA1 testing programs. J Clin Oncol 2000, 18: 2135–2142.PubMed
23.
Zurück zum Zitat Tercyak KP, Lerman C, Peshkin BN, Hughes C, Main D, Isaacs C, Schwartz MD: Effects of coping style and BRCA1 and BRCA2 test results on anxiety among women participating in genetic counselling and testing for breast and ovarian cancer risk. Health Psychol 2001,20(3):217–222. 10.1037/0278-6133.20.3.217CrossRefPubMed Tercyak KP, Lerman C, Peshkin BN, Hughes C, Main D, Isaacs C, Schwartz MD: Effects of coping style and BRCA1 and BRCA2 test results on anxiety among women participating in genetic counselling and testing for breast and ovarian cancer risk. Health Psychol 2001,20(3):217–222. 10.1037/0278-6133.20.3.217CrossRefPubMed
24.
Zurück zum Zitat Lerman C, Hughes C, Lemon SJ, Main D, Snyder C, Durham C, Narod S, Lynch HT: What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. J Clin Oncol 1998, 16: 1650–1654.PubMed Lerman C, Hughes C, Lemon SJ, Main D, Snyder C, Durham C, Narod S, Lynch HT: What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. J Clin Oncol 1998, 16: 1650–1654.PubMed
25.
Zurück zum Zitat Lodder L, Frets PG, Trijsburg RW, Klijn JG, Seynaeve C, Tilanus MM, Bartels CC, Meijers-Heijboer EJ, Verhoog LC, Niermeijer MF: Attitudes and distress levels in women at risk to carry a BRCA1/BRCA2 gene mutation who decline genetic testing. Am J Med Genet 2003,119A(3):266–272. 10.1002/ajmg.a.10168CrossRefPubMed Lodder L, Frets PG, Trijsburg RW, Klijn JG, Seynaeve C, Tilanus MM, Bartels CC, Meijers-Heijboer EJ, Verhoog LC, Niermeijer MF: Attitudes and distress levels in women at risk to carry a BRCA1/BRCA2 gene mutation who decline genetic testing. Am J Med Genet 2003,119A(3):266–272. 10.1002/ajmg.a.10168CrossRefPubMed
26.
Zurück zum Zitat Brain K, Soldan J, Sampson J, Gray J: Genetic counselling protocols for hereditary non-polyposis colorectal cancer: a survey of UK regional genetics centres. Clin Genet 2003,63(3):198–204. 10.1034/j.1399-0004.2003.00039.xCrossRefPubMed Brain K, Soldan J, Sampson J, Gray J: Genetic counselling protocols for hereditary non-polyposis colorectal cancer: a survey of UK regional genetics centres. Clin Genet 2003,63(3):198–204. 10.1034/j.1399-0004.2003.00039.xCrossRefPubMed
27.
Zurück zum Zitat Aktan-Collan K, Mecklin JP, de la Chapelle A, Peltomaki P, Uutela A, Kaariainen H: Evaluation of a counselling protocol for predictive genetic testing for hereditary non-polyposis colorectal cancer. J Med Genet 2000,37(2):108–113. 10.1136/jmg.37.2.108PubMedCentralCrossRefPubMed Aktan-Collan K, Mecklin JP, de la Chapelle A, Peltomaki P, Uutela A, Kaariainen H: Evaluation of a counselling protocol for predictive genetic testing for hereditary non-polyposis colorectal cancer. J Med Genet 2000,37(2):108–113. 10.1136/jmg.37.2.108PubMedCentralCrossRefPubMed
28.
Zurück zum Zitat Julian-Reynier C, Welkenhuysen M, Hagoel L, Decruyenaere M, Hopwood P, CRISCOM Working Group: Risk communication strategies: state of the art and effectiveness in the context of cancer genetic services. Eur J Hum Genet 2003,11(10):725–736. 10.1038/sj.ejhg.5201037CrossRefPubMed Julian-Reynier C, Welkenhuysen M, Hagoel L, Decruyenaere M, Hopwood P, CRISCOM Working Group: Risk communication strategies: state of the art and effectiveness in the context of cancer genetic services. Eur J Hum Genet 2003,11(10):725–736. 10.1038/sj.ejhg.5201037CrossRefPubMed
Metadaten
Titel
A Counselling Model for BRCA1/2 Genetic Susceptibility Testing
verfasst von
Iris van Oostrom
Aad Tibben
Publikationsdatum
01.02.2004
Verlag
BioMed Central
Erschienen in
Hereditary Cancer in Clinical Practice / Ausgabe 1/2004
Elektronische ISSN: 1897-4287
DOI
https://doi.org/10.1186/1897-4287-2-1-19

Weitere Artikel der Ausgabe 1/2004

Hereditary Cancer in Clinical Practice 1/2004 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.